title: Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
abstract: In a previous pharmacokinetic/pharmacodynamic study in nonbleeding hemophilia patients, variability in laboratory response to recombinant factor VIIa (rFVIIa) 90 μg/kg was noted, and the patients were described as delayed or rapid laboratory responders based on time to clot formation. The current study determined whether in-vitro experiments could reproduce previous in-vivo findings; whether the delayed laboratory response to rFVIIa 90 μg/kg is improved by spiking with high-dose rFVIIa or rFVIIa analogue (vatreptacog alfa); whether a dose-response is observed with our method. In-vitro experiments were conducted in our previous patient cohort using rFVIIa 1.28 and 3.84 μg/ml and vatreptacog alfa 0.28 and 0.56 μg/ml. Whole blood studies were conducted using the Hemodyne Hemostasis Analysis System (platelet contractile force, clot elastic modulus, force onset time) and rotational thromboelastometry (clotting time, maximum clot firmness). Spiking with rFVIIa 1.28 μg/ml showed the same distribution of delayed and rapid laboratory response as observed previously. Increasing in-vitro rFVIIa concentrations improved the coagulation parameters; however, there remained delayed and rapid responders. Vatreptacog alfa improved the coagulation parameters at all concentrations tested, and the 0.56 μg/ml concentration normalized the force onset time, platelet contractile force, clot elastic modulus and clotting time parameters. A dose-response was observed with both assays. There was good agreement between the laboratory responses obtained after intravenous administration of rFVIIa 90 μg/kg and in-vitro spiking studies. Escalating rFVIIa and vatreptacog alfa concentrations improved coagulation parameters in all patients compared to rFVIIa 1.28 μg/ml. Vatreptacog alfa produced more pronounced coagulation effects at lower concentrations than rFVIIa; and the 0.56 μg/ml concentration completely normalized responses in all patients.
authors.affiliation: Coagulation Advancement Laboratory, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA. dbrophy@vcu.edu
authors.forename: Donald F
authors.initials: DF
authors.lastname: Brophy
authors.forename: Erika J
authors.initials: EJ
authors.lastname: Martin
authors.forename: J Christian
authors.initials: JC
authors.lastname: Barrett
authors.forename: Melinda E
authors.initials: ME
authors.lastname: Nolte
authors.forename: Janice G
authors.initials: JG
authors.lastname: Kuhn
authors.forename: Ulla
authors.initials: U
authors.lastname: Hedner
authors.forename: Mirella
authors.initials: M
authors.lastname: Ezban
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects*; D002478:Cells, Cultured; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000494:pharmacology*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology*; D013916:Thrombelastography; D013997:Time Factors; D014768:Virginia
chemical_list: D011994:Recombinant Proteins; C000596433:vatreptacog alfa; C103587:recombinant FVIIa; D015942:Factor VIIa